Clover Biopharmaceuticals Ltd. (HK:2197)
:2197
Top Page
Clover Biopharmaceuticals Ltd.
(2197)
Select Model
Select Model
Rating:52Neutral
Price Target:
HK$2.00
▼(-15.61% Downside)
Action:ReiteratedDate:11/14/25
Clover Biopharmaceuticals' overall stock score is primarily impacted by its weak financial performance, characterized by persistent losses and negative cash flows. While technical analysis indicates positive momentum, the company's negative valuation metrics, including a negative P/E ratio, further weigh down the score. The absence of earnings call data and corporate events means these factors do not influence the score.
Positive Factors
Proprietary protein subunit technology
A reusable protein subunit vaccine platform provides a durable competitive advantage: it can be adapted to new antigens, supports scalable manufacturing, and often has favorable safety profiles. Over months this platform boosts pipeline flexibility and licensing potential for sustained R&D efficiency.
Negative Factors
Persistent operating losses
Ongoing net losses erode retained capital and make internal funding of trials and commercialization difficult. Persisting deficits over months force reliance on external financing, which can be dilutive or costly, constraining long-term investment and strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary protein subunit technology
A reusable protein subunit vaccine platform provides a durable competitive advantage: it can be adapted to new antigens, supports scalable manufacturing, and often has favorable safety profiles. Over months this platform boosts pipeline flexibility and licensing potential for sustained R&D efficiency.
Read all positive factors
Clover Biopharmaceuticals Ltd. (2197) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.96B
Dividend YieldN/A
Average Volume (3M)29.82M
Price to Earnings (P/E)―
Beta (1Y)2.49
Revenue Growth79.98%
EPS Growth-3.40%
CountryHK
Employees300
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.09
Shares Outstanding1,298,037,500
10 Day Avg. Volume32,349,599
30 Day Avg. Volume29,824,166
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.17
Price to Sales (P/S)7.39
P/FCF Ratio-0.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Clover Biopharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developi...
How the Company Makes Money
Clover Biopharmaceuticals generates revenue primarily through the development and commercialization of its vaccine products. Key revenue streams include government and institutional contracts for vaccine supply, partnerships with pharmaceutical co...
Clover Biopharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
20
Very Negative
Balance Sheet
15
Very Negative
Cash Flow
25
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 51.77M | 38.42M | 39.26M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -659.39M | -672.94M | 24.24M | -475.64M | -66.27M | 0.00 |
| EBITDA | -881.50M | -916.54M | -45.07M | -2.37B | -2.23B | -335.04M |
| Net Income | -909.58M | -903.43M | -138.54M | -2.45B | -6.02B | -915.87M |
Balance Sheet | ||||||
| Total Assets | 594.21M | 812.74M | 2.10B | 4.69B | 5.35B | 1.19B |
| Cash, Cash Equivalents and Short-Term Investments | 395.74M | 427.53M | 766.26M | 1.64B | 2.87B | 806.51M |
| Total Debt | 13.05M | 89.64M | 334.45M | 354.37M | 67.92M | 22.32M |
| Total Liabilities | 2.30B | 2.45B | 2.83B | 5.36B | 4.13B | 2.17B |
| Stockholders Equity | -1.71B | -1.64B | -732.83M | -668.14M | 1.22B | -982.74M |
Cash Flow | ||||||
| Free Cash Flow | -246.53M | -290.11M | -737.05M | -1.80B | -998.07M | 363.13M |
| Operating Cash Flow | -246.59M | -288.49M | -727.88M | -1.69B | -917.75M | 476.93M |
| Investing Cash Flow | 13.95M | 3.17M | -6.16M | -37.51M | 112.12M | -394.12M |
| Financing Cash Flow | 127.58M | -51.50M | -142.41M | 483.14M | 3.06B | 316.85M |
Clover Biopharmaceuticals Ltd. Technical Analysis
Positive
2.37
Price Trends
2.27
Positive
2.41
Positive
1.84
Positive
Market Momentum
0.19
Negative
71.11
Negative
82.87
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2197, the sentiment is Positive. The current price of 2.37 is below the 20-day moving average (MA) of 2.41, above the 50-day MA of 2.27, and above the 200-day MA of 1.84, indicating a bullish trend. The MACD of 0.19 indicates Negative momentum. The RSI at 71.11 is Negative, neither overbought nor oversold. The STOCH value of 82.87 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2197.
Clover Biopharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | HK$3.96B | -13.26 | 11.40% | ― | 79.98% | -3.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$12.11B | 5.89 | 18.28% | ― | 59.70% | 239.97% | |
48 Neutral | HK$1.32B | -4.06 | -102.50% | ― | ― | 81.67% | |
44 Neutral | HK$2.30B | -3.21 | -137.11% | ― | ― | -18.99% | |
44 Neutral | HK$806.45M | -6.45 | 191.92% | ― | ― | 83.89% | |
43 Neutral | HK$1.23B | -2.47 | -27.44% | ― | -57.84% | 24.58% |
* Healthcare Sector Average
HK:2197
Clover Biopharmaceuticals Ltd.
3.05
2.84
1352.38%
HK:9939
Kintor Pharmaceutical Ltd
2.68
1.58
143.64%
HK:2142
HBM Holdings Ltd.
13.69
7.22
111.59%
HK:2179
Jiangsu Recbio Technology Co., Ltd. Class H
4.80
-2.12
-30.64%
HK:2257
Sirnaomics Ltd.
7.35
4.25
137.10%
HK:6628
Transcenta Holding Limited
2.79
1.68
151.35%
Clover Biopharmaceuticals Ltd. Corporate Events
Clover Launches Phase 2 Trial of Combination Respiratory Vaccines in Older Adults
Jan 12, 2026
Clover Biopharmaceuticals has initiated a Phase 2 clinical trial in Australia for its protein-based combination respiratory vaccine candidates SCB-1022 (targeting RSV and hMPV) and SCB-1033 (targeting RSV, hMPV and PIV3), both built on its prefusi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.